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Abstract
Diagnosis of acute lung allograft rejection is currently based on transbronchial lung biopsies. Additional methods to
detect acute allograft dysfunction derived from plasma and bronchoalveolar lavage samples might facilitate diagnosis
and ultimately improve allograft survival. This review article gives an overview of the cell profiles of bronchoalveolar
lavage and plasma samples during acute lung allograft rejection. The value of these cells and changes within the
pattern of differential cytology to support the diagnosis of acute lung allograft rejection is discussed. Current findings
on the topic are highlighted and trends for future research are identified.
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Background
Lung transplantation is an established treatment option
for selected patients with advanced lung disease [1, 2].
However, despite improvement in surgical, postoperative
and immunosuppressive management, the overall sur-
vival after lung transplantation remains lower than for
recipients of other solid organ transplants [2, 3]. This is
mainly due to development of chronic lung allograft dys-
function (CLAD), of which bronchiolitis obliterans syn-
drome (BOS) is the most common phenotype, being
observed in more than 75 % of lung transplant recipients
after 10 years [4, 5].
A major risk factor for the development of CLAD is
the occurrence of repeated episodes of higher grade
acute lung allograft rejection (AR) [6–8]. Acute lung AR,
together with infections that by itself might trigger AR,
is one of the most common complications occurring
early after lung transplantation and affects more than
30 % of adult lung transplant recipients within the first
year post transplantation [2].
Acute lung AR is suggested by a decline of lung func-
tion that is not explained by other reasons such as infec-
tion, left-sided heart failure or weight gain. The gold
standard for AR diagnosis is the analysis of serial
transbronchial lung biopsies (TBB) [9]. This method,
however, is invasive and carries the risk of pulmonary
bleeding and pneumothorax [10, 11]. Moreover, interob-
server variability and sampling error limit the reliability
of this method [12, 13].
Various attempts have been undertaken to validate al-
ternative diagnostic methods, including clinical and/or
radiological criteria. However, these patterns only allow
delayed and retrospective diagnosis [14] and are of
limited sensitivity [14, 15]. Moreover, cough, dyspnoea,
low-grade fever, perihilar infiltrates and deterioration of
pulmonary function may appear in other common con-
ditions after transplantation and do not distinguish AR
from infection [14, 16].
Alternatively, alterations in bronchoalveolar lavage
(BAL) and plasma samples have been examined for spe-
cific changes during acute lung AR. Sampling cells by
BAL bronchoscopy is less invasive than TBB and allows
for repetitive harvesting. Although rare, complications of
BAL have been observed and include fever, wheezing or
bleeding [17]. Being able to diagnose acute lung AR in
peripheral blood would be desirable for various reasons.
Peripheral blood is easily accessible and complications
are rare. However, peripheral blood may not reliably re-
flect processes in the lung and might thus not reach high
specificity. The lung allograft rejection gene expression
observational study (LARGO) is currently analysing new
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non-invasive techniques to assess biomarkers in periph-
eral blood. The study has shown encouraging results but
further research is needed [18].
Since both BAL and plasma samples have the ad-
vantage of being fast and less invasive in comparison
with TBB, we reviewed here the evidence for the use
of BAL and plasma samples for detection of acute
lung AR in lung transplant recipients. This article
aims to provide answers to the question whether
changes in cell count or percentage of cellularity ap-
pear to be specific for acute lung AR and whether
they precede clinical symptoms and decline in lung
function. An illustrative algorithm for the likelihood
of acute AR depending on BAL and plasma cellularity
is provided in Fig. 1.
More specifically, this review summarises the experi-
mental and clinical evidence on the differential cellular-
ity profiles in BAL and plasma samples during acute
Fig. 1 Algorithm based on serum and BAL cell count and analysis. This descriptive algorithm attempts to describe probabilities for acute AR in
lung transplant recipients and as such might assist in decision-making to increase or decrease the likelihood for acute AR in the context of the
clinical presentation. Since results from studies with very different designs have been included direct translation in a clinical setting is not feasible
and the use of this algorithm does not obviate the need for biopsy to confirm or exclude histology-proven acute rejection. It is important to note
that in the absence of an explicit allograft infection, in which bronchoscopy might be postponed in favour of empiric antimicrobial treatment,
any lung transplant recipient with a lung functional drop (FEV1 > 10 %) should undergo diagnostic bronchoscopy independent of blood analysis.
* Numbers may vary between different studies. ** Absence of microbiological evidence for infection
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lung AR. Current findings on this topic are discussed
and areas for future research are identified.
Methods
We searched the electronic databases Medline
(Bethesda, MD, USA: U.S. National Library of Medicine),
EMBASE (Amsterdam, NL: Elsevier B.V.) and Web of
Science Core Collection (New York, NY, USA: Thomson
Reuters). Medical subject heading (MeSH) terms in-
cluded „bronchoalveolar lavage fluid/cytology“ in com-
bination with “graft rejection” and “lung transplantation”
for BAL and “blood/cytology” or “plasma/cytology” in
combination with “graft rejection” and “lung transplant-
ation” for data on plasma samples. Publications were eli-
gible if they provided information on cytological changes
in BAL or peripheral blood during acute lung AR. We
considered articles published in English until June 1,
2015. This included experimental studies, prospective
and retrospective clinical studies, review articles and
case reports. No other restrictions were applied. We
then selected those articles that fulfilled our inclusion
criteria. Additionally, we scanned the references of all se-
lected articles to find additional literature that was re-
lated to our research question. Finally, 54 papers were
eligible to be included in our review. An ordered list of
the type and number of articles included is provided in
Table 1.
We then evaluated the selected articles and compiled
an extensive table, listing every cell type, the reference
that mentioned these parameters as well as the observed
data. While writing the review article more papers were
drawn on for background information. Each author
reviewed the entire document and provided input before
the final manuscript was completed.
Cells in BAL and plasma samples
AR has been recognised as an interacting process of T
cell subpopulations, macrophages, granulocytes and B
cells [19, 20]. Cellular changes occurring during acute
lung AR can be observed either directly in the allograft
using biopsies or, alternatively, in bronchoalveolar lavage
fluid or plasma samples.
Bronchoalveolar lavage allows recovering cells and
proteins present on the epithelial surface of the lower re-
spiratory tract [21]. Originally, BAL fluid was the
primary method to identify lung infections in immuno-
suppressed patients since viral, bacterial, fungal and
protozoal infections are detected with high sensitivity
and specificity [17, 22]. Achterrath and colleagues were
the first to look at BAL fluid for the study of differential
cytology during acute lung AR, using a canine model
[23]. Since then, various investigators have examined cel-
lular changes in BAL samples during acute lung AR.
Moreover, in the context of prognosis, the presence of
eosinophils in BAL (≥2 %) has been associated with the
development of CLAD and reduced overall survival [24].
Some lung transplant centres routinely collect BAL sam-
ples after lung transplantation (“surveillance bronchos-
copy”) [24, 25]. However, the confounder of concurrent
infections and the lack of specimen standardization and
equipment limit the routine use of BAL to diagnose
acute AR [17].
The technique of retrieving BAL samples might vary
between different centres [26]. Differences concern the
means of harvesting, the discard of the first aliquot as
well as the pre-analytic phase. BAL fluid is analysed for
microbiological infiltrates, total cell count and cytology.
The number of different cells detected is divided by the
total cell count and expressed as percentages. To deter-
mine lymphocyte phenotypes flow cytometry is
performed [27]. Table 2 provides an overview of the
bronchoalveolar lavage fluid cell profile in different
populations.
For this review article, we selected cells that are rou-
tinely analysed in clinical diagnostics, including neutro-
phils, lymphocytes, eosinophils, basophils, monocytes
and alveolar macrophages (AM). Natural killer cells (NK
cells) and B lymphocytes (B cells) as subgroups of lym-
phocytes were considered separately. In order to keep
this paper close to clinical practice, T cell subgroups
such as CD25+ regulatory cells, CD8+ T cells or T cells
with other clusters of differentiation have not been in-
cluded in this review article although findings have
emerged on these recently [28–30]. Tables 3 and 4 pro-
vide a list of cells studied with the observed direction of
change during acute lung AR and the respective
references.
Neutrophils
Neutrophils are an integral part of innate immunity
and constitute the largest portion of circulating white
blood cells [31]. They exhibit phagocytic functions
and secrete toxic granules containing granzyme B,
perforin and myeloperoxidase, thus, playing a major
role in anti-microbial defence [31]. They are rapidly
drawn to sites of inflammation, apparently by the
Table 1 Types and number of references included in this
review article
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chemotactic factors IL-8 and IL-17 [32]. Neutrophil
defence mechanisms have been associated with several
conditions in the lung including viral infections (e.g.
Influenza and RSV) [33, 34].
In the context of BAL fluid analysis neutrophils have
emerged as key mediators of a recently identified CLAD
phenotype, which has been defined as neutrophilic re-
versible allograft dysfunction (NRAD). NRAD is charac-
terised by BAL neutrophilia (≥15 %) without any other
signs for infection. These patients respond well to long-
term macrolide therapy [35]. A recent study, however,
has challenged this NRAD phenotype since response to
azithromycin was found to be independent of neutrophil
count [36].
Clinical data on neutrophils during acute lung AR
point toward an increase in neutrophils in BAL samples
[32, 37–40]. A prospective study with 20 lung or heart-
lung transplant recipients found increased numbers of
Table 2 Percentage of cellularity in BAL in different populations
Basophils Eosinophils Neutrophils Lymphocytes AM Total cell count
Healthy, non-smoking
individuals [78]
<1 % <2 % <3 % <10–15 % >85 % 31–350/μl
Smokers [78, 101, 102] <3 % 3 % <7 % 95 %; 3–5-fold
increase of total cells
80–1100/μl; 3-fold
increase of total cells
Stable lung transplant
recipients [17, 64]




≥2 % >0 % 15–30 % 10–60 % 30–70 % 200 - > 700/μl;
increased, high variance
Association with AR
- Direction ↑ ↑ ↑ ↑ ↓ ↑
- Replicability moderate moderate high high high
Table 3 Observed pattern of cells in BAL samples during acute lung AR
Cell BAL Reference Sensitivity Specificity Cut-off
Basophils ↑ [37, 38]
↑ (rare) [25]
Eosinophils ↑ [59] (experimental)




Neutrophils ↑ [32, 37–40] 74 % 82 % ≥12 %
0 [42, 43]
Lymphocytes ↑ [47–49] (experimental)










NK cells ↓ [25, 85]
B cells ↑ (rare) [25]
↑0 [85]
Monocytes ↓ [25]
Macrophages ↑ [47] (experimental)
↓ [27, 32, 40–42, 50]
0, No correlation
↑, Increased
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neutrophils during rejection episodes that occurred after
post-operative day 180. Furthermore, BAL neutrophilia ≥
12 % after post-operative day 31 diagnosed acute AR
with a specificity of 82 % and a sensitivity of 74 %. Even
though this change is not specific for rejection alone, in-
creased neutrophils in BAL should be considered suspi-
cious for rejection when occurring after the first
postoperative month [37, 38, 40].
Moreover, neutrophils in BAL have been shown to cor-
relate with severity of acute AR in a number of studies
[25, 32, 41]. However, one should remind that the broad
use of macrolides complicates interpretations of BAL neu-
trophilia between current studies and studies performed
before the diffusion of macrolides less than a decade ago.
In contrast to these findings, other studies found no
association between neutrophil percentage and acute
lung AR [42, 43] or activation of neutrophils during epi-
sodes of rejection [43].
In addition to these observational data, a gene-based
diagnostic classifier for acute lung AR has been proposed.
Patil and colleagues found that increased BAL neutrophil
gene expression was associated with acute AR. The num-
ber of neutrophils in biopsies also increased during rejec-
tion episodes, yet this characteristic was no better
discriminator than the gene-based classifier [44].
Little data exists on blood neutrophils during acute
AR. In one prospective study blood neutrophil count
was not associated with acute lung or cardiac allograft
rejection. Yet, a lacking increase of neutrophils in the
presence of raised eosinophils was considered a specific
and early sign for clinically relevant rejection [45].
Lymphocytes
Lymphocytes are mediators of the adaptive and innate
immune system and consist of several subtypes includ-
ing T lymphocytes (T cells), B cells and NK cells. Most
studies focusing on lymphocytes make conclusions on
lymphocytes in general and do not address the subtypes.
T cells have been identified as the most important medi-
ators of acute AR and are thus of special interest in
transplantation medicine [46].
Experimental data points towards an increase in BAL
lymphocytes during acute lung AR: Data obtained from
an experimental rejection model using rats [47, 48] and
dogs [49] described an increase in the number of BAL T
lymphocytes few days after onset of AR [47, 48]. More-
over, the increase of BAL lymphocytes was more pro-
nounced with higher grades of rejection [49].
In a clinical setting, all reviewed articles found increased
BAL lymphocyte counts during acute AR, however at dif-
ferent time points [32, 37, 38, 42]. Lymphocytes have been
reported to be elevated (≥15 %) during the first postopera-
tive month, with a specificity of 77 % and sensitivity of
64 % (p < 0.05) to diagnose acute AR. Specificity for lym-
phocytes for infection was higher during months 1 to 6
(86 %), while sensitivity remained unchanged [37, 38]. In a
prospective study, BAL lymphocytes were found to be
higher during grade A2 mild acute AR compared with
matched controls at a median sampling time of seven
months [42].
However, increased levels of BAL lymphocytes show an
insufficient sensitivity to diagnose acute AR [14, 50, 51].
BAL lymphocytosis of ≥ 20 % was very specific (96 %) but
not sensitive (40 %) to diagnose acute AR [14].
Increased BAL lymphocytes are not exclusively found
in acute AR but have been observed during other post-
transplant complications [27, 40]. More specifically, BAL
lymphocyte percentage was found elevated during acute
AR (19 % ± 5.6), infection (22.5 % ± 4.5) and in CLAD
(29.5 % ± 7.9), although these findings did not reach sig-
nificance [40]. Another research group investigating
acute AR and infection observed the highest number of
lymphocytes during episodes of rejection. In this study,
BAL lymphocyte percentage > 20 % diagnosed acute AR
with a specificity of 92.5 % and a sensitivity of 65 %
(positive predictive value (PPV) 79.5 %, negative predict-
ive value (NPV) 85.4 %). However, in 11 % of BAL
samples with significantly increased BAL lymphocytes
infection was identified (four of five patients had CMV
pneumonitis) [27]. In one of the first prospective studies
comparing BAL and TBB cell profiles mean BAL
lymphocyte count was significantly higher in acute AR
than in infection, treated acute AR and CLAD. However,
distinguishing between these conditions based on lym-
phocytes levels was not possible due to considerable
overlap between the groups. Lymphocyte percentage
Table 4 Observed patterns of cells in plasma samples during
acute lung AR
Cell Plasma Reference Sensitivity Specificity Cut-off
Basophils ↑ [37, 38] 42 % 94 % ≥2 %
Eosinophils ↑ [45] 72 % 75 % Increase≥ 9
cells/μl
Neutrophils 0 [45]








Early BAL neutrophilia in absence of an infection should raise
suspicion for acute lung AR.
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exceeded the upper level of normal (15 %) in 23 % of
BAL samples with acute AR, but also in 13 % of samples
with infection. Although rarely seen, BAL lymphocytosis
of > 25 % was suggestive for the diagnosis of acute AR
[50]. Greenland and colleagues calculated the odds for
having rejection rather than infection per standard devi-
ation increase of lymphocytes in BAL samples with ei-
ther infection or biopsy-confirmed rejection grade ≥A1.
Raised percentages of lymphocytes (>12 %) turned out
to be associated with greater odds (OR = 2.04) of rejec-
tion [25].
The correlation between BAL lymphocyte count and
rejection grade in TBB show inconsistent findings. Sev-
eral studies found no association between lymphocytosis
in BAL and histopathological rejection grade [27, 50, 51]
whereas others described a correlation between BAL
lymphocyte count and grade of acute AR in biopsy spec-
imens [14, 25, 32].
Data about lymphocytes in peripheral blood differs
considerably between studies [37, 38, 40]. Blood lympho-
cytes were raised significantly during acute AR between
day 31 and day 180 after transplantation compared to
controls with neither rejection nor infection [37, 38]. In
contrast, peripheral blood lymphocytes did not change
significantly in another study [40].
Eosinophils
Eosinophils are bone marrow-derived granulocytes
and account for less than 5 % of circulating leuko-
cytes. Upon stimulation by interleukins (IL) such as
IL-4, IL-5 and IL-13 eosinophils produce reactive oxy-
gen species and toxic granule proteins (e.g. eosinophil
cationic protein and major basic protein) [52]. Eosin-
ophils have been associated with various pulmonary
conditions such as asthma, eosinophilic granulomato-
sis with polyangiitis (“Churg-Strauss syndrome”), drug
reactions, helminthic infections, hypereosinophilic
syndrome as well as acute and chronic eosinophilic
pneumonia [16, 53–56]. More specifically, eosinophils
have been shown to damage the lung by degrading
connective tissue and injuring epithelial and micro-
vascular structures [57, 58].
Raised BAL eosinophils were found to be a marker
of early lung AR in rats [59]. This result is in line
with previous experimental data where raised eosino-
phils in blood and allograft were associated with the
rejection process in other solid organs including the
kidney, liver and heart [60–63].
Increased numbers of eosinophils in peripheral
blood precede clinically significant AR in both pul-
monary and cardiac transplant recipients. This was
first shown in a retrospective study with 58 pulmon-
ary and 56 cardiac allograft recipients. The mean
maximum eosinophil count in the three days before
treated lung AR was 140/μl, which was significantly
higher than when rejection or infection were absent.
An increase in blood eosinophils of ≥ 9/μl in allograft
recipients had a sensitivity of 72, a specificity of 75
and a modest PPV of 51 % for the detection of acute
AR during postoperative month one. Trull and co-
workers therefore suggested measuring blood eosino-
phils daily during the first postoperative month to de-
tect acute AR at an early stage [45].
Eosinophils have appeared in BAL fluid of patients with
good outcome after lung transplantation, making up < 1 %
of total cells [64]. Several clinical studies have found an as-
sociation between increased eosinophils in BAL and acute
lung AR [25, 27, 37, 38, 43]. Greenland and co-workers
found significantly raised eosinophils during acute AR.
However, eosinophils were detected in < 10 % of samples.
Applying a multivariate, linear regression model the au-
thors identified eosinophils > 0 % as one of four high-risk
features for rejection (besides monocytes < 75, NK cells <
5 and CD25+ cells > 8 %). If all of these features were ab-
sent, acute AR was unlikely with a NPV of > 96 % [25]. Be-
sides, levels of cytotoxic eosinophil cationic protein were
found to be increased in transplant recipients during acute
AR or infection, which points towards activation of eosin-
ophils in these conditions [43, 65, 66].
A relation between the amount of eosinophils in BAL
and severity of acute AR has been reported [41, 67]. In a
retrospective study performed in a large cohort, Vos and
colleagues found that raised eosinophils in BAL fluid
correlated with increasing grade A severity in biopsies
with grade A rejection alone or combined A and B rejec-
tion [41].
Moreover, eosinophilia ≥ 2 % in BAL seems to cor-
relate with worse outcome after lung transplantation
[24]. In a multivariate model Verleden and colleagues
identified BAL eosinophilia as the most important
risk factor for CLAD development and overall mortal-
ity. The investigators indicated that acute rejection
with detectable eosinophils in BAL might constitute a
different form of acute AR. This phenotype might re-
spond less to treatment and may thus be associated
with worse outcome [24]. This hypothesis could also
explain the observation that eosinophilia tends to be
associated with more aggressive episodes of acute AR
[68]. Alternatively, altered antioxidant defence might
render transplant recipients more susceptible for eo-
sinophil cytotoxic agents, as suggested by Riise and
colleagues [69].
High BAL lymphocyte counts are associated with acute lung AR but
are also found in other complications following lung transplantation.
In most studies, BAL lymphocytosis showed an acceptable specificity
for AR. Sensitivity, however, is low.
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Not all investigators reported increased BAL eosino-
phils during acute lung AR [32, 42, 70]. A retrospective
study found no statistically significant difference be-
tween eosinophil percentage in BAL fluid in patients
with acute AR and patients without AR or infection.
However, BAL samples of transplant recipients con-
tained more eosinophils than those of non-transplanted
controls during both event-free episodes and acute AR
[70]. In another study, eosinophil number and percent-
age were low and hardly variable (median 0 %, interquar-
tile range (IQR) 0–0.8 %) during acute AR [32].
Several mechanisms for the pathogenesis and activa-
tion of eosinophils during acute AR exist. Eosinophils in-
jure the graft by releasing cytotoxic agents such as
eosinophil cationic protein [65, 68]. Activation of eosino-
phils by helper T lymphocytes through IL-3 and IL-5
and by macrophages through IL-1 has been suggested
[16, 71, 72]. However, Bewig and colleagues found no
correlation between lymphocytes expressing IL-5 and
the number of eosinophils in BAL [16]. This group also
found that patients with BAL eosinophilia during acute
AR responded well to steroids, which was confirmed in
other studies [16, 73].
Eosinophils in allografts are not confined to AR but
have been found in transplant recipients with viral, fun-
gal and bacterial infection [68]. High eosinophils in BAL
are indicative of acute AR if four conditions are fulfilled:
Eosinophilia should be temporary, accompanied by clin-
ical signs of rejection, in the absence of infection and re-
spond to anti-rejection therapy [16].
Basophils
Basophils are circulating granulocytes representing
less than 1 % of blood leukocytes in steady-state con-
ditions of non-transplanted individuals [74]. Upon
stimulation by inflammatory signals they rapidly ex-
pand within the bone marrow and are distributed to
the blood, spleen and liver [75]. Invasion of the lungs
has also been observed and might be of major im-
portance in the context of allograft dysfunction and
acute AR [75]. While the exact function of basophils
remains unknown to date, recent evidence suggests
that these cells play a critical role in a variety of im-
munologic disorders [76].
The role of basophilic granulocytes in lung trans-
plant recipients has not yet been elaborated in detail.
However, mild peripheral blood basophilia and their
presence in BAL fluid have been associated with acute
AR in clinical studies [25, 37, 38]. As such, Tikkanen
and co-workers analysed samples from peripheral
blood, BAL and TBB of 20 heart and heart-lung allo-
graft recipients with and without signs of rejection in
a prospective study. To assess the cell profiles over
post-transplant time course, the samples were arbi-
trarily divided in three groups (1–30 days; 31–180
days; >180 days). Throughout follow-up, blood baso-
philia of ≥ 2 % was indicating acute AR with a very
high specificity (94 %). Moreover, the number of ba-
sophils was increased in BAL fluid in patients with
acute AR compared to controls during the first post-
operative month [37]. In a recent retrospective study
similar results were obtained. This work constitutes
the most extensive analysis on BAL cellularity in lung
transplant recipients so far [77]. BAL fluid collected
from almost all patients (317 of 356) who underwent
lung transplantation at the University of California
(UCSF) between 1997 and 2011 was analysed. Al-
though rarely detected in BAL samples, the presence
of basophils was associated with AR [25], confirming
the role of basophils as a potential surrogate marker
of AR.
Monocytes and alveolar macrophages
Monocytes are the largest cells in blood and account for
3–8 % of all blood cells. Upon recruitment to different tis-
sues, monocytes undergo maturation into macrophages
[25]. Alveolar macrophages account for > 85 % of cells re-
trieved in BAL fluid of healthy non-transplanted individ-
uals [78]. They play an important role in anti-microbial
defence, inflammatory and immune reactions as well as
protecting lung tissue from protease attack [21].
BAL inflammatory macrophages were raised in an
experimental rejection model using rats. While
acute AR occurred in all allotransplants on day two
after transplantation macrophage number and per-
centage increased later in the rejection process, on
day six [47].
Results on BAL macrophages are not consistent. AM
percentage in BAL shows a trend towards reduction dur-
ing acute AR [25, 32, 40, 42]. These findings, however,
are not specific and are also observed during other post-
transplant complications such as infection and BOS [27,
50]. BAL macrophage percentage was reduced in infec-
tion and both acute AR grade I (47.8 % ± 14.2) and grade
II-III (42.7 % ± 9.9) as compared to normal controls
Eosinophils are rarely present in BAL; however, if detected and
elevated in BAL and if other causes are excluded, suspicion for acute
AR should be raised. Peripheral blood eosinophilia might indicate
clinically significant rejection. Blood differential cellularity should be
examined regularly.
Mild peripheral blood basophilia and their presence in BAL fluid have
been associated with acute AR in clinical studies.
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(72.8 % ± 4.4) [40]. Similarly, BAL macrophage percent-
age was significantly lower in patients with acute AR
(78 %) than in matched controls (91 %) at a median
sampling time of seven months [42]. The same trend
was observed in another study, yet the total macrophage
cell count did not differ between rejecting patients and
controls. The macrophage percentage was lower during
acute AR due to higher neutrophil and lymphocyte
counts [32]. In a scoring system developed to identify
strong and independent parameters of AR, Greenland
and colleagues found that higher levels of monocytes
were negatively associated with acute AR. Conversely,
monocytes < 75 % correlated independently with rejec-
tion scores ≥A1 in a multivariate, linear regression
model (OR 2.41) and were identified as one of four
high-risk features for rejection (see eosinophils) [25].
AM counts have also been shown to correlate in-
versely with the histopathological grade of rejection [41,
50]. In a prospective study, Clelland and colleagues
found an association between BAL macrophage number
and the severity of acute AR: A lower number of macro-
phages in BAL correlated with a higher grade of rejec-
tion on transbronchial biopsies [50]. This trend was also
observed in a retrospective study [41].
NK cells
NK cells are a subset of lymphocytes with characteris-
tics of both innate and adaptive immunity [79]. Their
role in immunity has not been entirely understood
but new views are emerging. In current understand-
ing, NK cells are important in eliminating viral infec-
tions and neoplastic cells [79]. Moreover, they can
both regulate adaptive immune responses by eliminat-
ing antigen-presenting cells and T cells [80–82] and
enhance such responses via cytokines such as inter-
feron gamma (IFN-γ) and tumour necrosis factor
alpha (TNF-α) [83, 84].
Few studies analysed NK cell count during acute lung AR,
however these have yielded encouraging results [25, 85].
Additionally, some studies examined NK cell activity during
periods of rejection [49, 86]. The discussion of these find-
ings is beyond the scope of this review.
NK cells have been reported to decline in BAL of
lung transplant patients during episodes of acute
lung AR [25, 85]. NK cell percentage was reduced in
patients with acute AR compared to non-rejecting
controls, however the difference did not reach
significance [85]. In a recent retrospective study
Greenland and colleagues found a decrease in NK
cell counts during acute AR and combined rejection
and infection but an increase in NK cell counts in
infection alone compared to healthy transplant
recipients [25].
These findings are in line with newer research on
NK cells: NK cells appear to be of pathogenic import-
ance in kidney rejection by responding to missing
host MHC ligands [87, 88] and in allograft tolerance
by eliminating donor antigen-presenting cells [83, 89,
90]. Deficiency in NK cells has been shown to en-
hance AR, as detected in biopsies taken from mice
[83]. According to a prospective study, NK cell num-
bers were raised in BAL fluid of stable lung trans-
plant recipients and patients with BOS compared to
non-transplanted individuals [91].
B cells
B cells are lymphocytes expressing immunoglobulin on
their surface, among other markers [92]. In their acti-
vated state as plasma cells B lymphocytes are the only
producers of antibody molecules. Additionally, B cells
activate T cells via antigen presentation [93] and organ-
ise the microarchitecture of lymphoid tissue [94, 95]. Re-
cent data showed that B cells play an important role in
the immunological response to an allograft, which goes
beyond the production of antibodies [92, 96]. Indeed,
studies on kidney rejection suggest an involvement of B
cells in acute – T cell-mediated – AR [92, 97, 98]. Few
data exist concerning the contribution of B cells to acute
lung AR. In addition, diagnosis and definition of
antibody-mediated rejection (AMR) is not well-defined
in lung transplant recipients [99]. In the context of acute
lung AR and BAL samples, increased numbers of B cells
have been associated with acute AR [25, 85]. Most sam-
ples, however, contained less than 2 % of B cells, pre-
cluding further conclusions [25].
Macrophage percentage in BAL samples is reduced in rejecting
patients. Since the total macrophage cell count was not found to be
different this finding must be due to higher neutrophil and
lymphocyte counts during acute lung AR.
Novel data identified NK cell count in BAL as a promising marker to
assess lung transplant recipients. Patients with an episode of acute
lung AR showed decreased numbers of NK cells. These data remain
to be confirmed. Since NK cells are not measured in most lung
transplant centres to date, clinical feasibility of such an assay has to
be investigated.
Antibody-producing B cells might play a role in the development of
AMR, which is still an ill-defined entity in the spectrum of lung allograft
dysfunction. Few studies suggested an increase of B cells in BAL fluid
during acute AR.
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Limitations
The studies included and discussed in our critical re-
view have several limitations. Most studies have a
retrospective design and report single centre experi-
ence [100]. Additionally, the methodological ap-
proaches and the patient cohorts are heterogeneous
and vary substantially. Along this line, diagnostic cri-
teria, immunosuppressive regimens, time points of
sample collection and histological analyses and statis-
tical evaluations differ between the studies.
More specifically, relying on one “unique” BAL cellular
profile to diagnose acute AR is questionable since BAL
cellular patterns differ according to the time-onset of
acute AR episodes. As shown in the study by Tikkanen
and colleagues, acute AR occurring early (1–180 days)
after transplantation was associated with increased lym-
phocytes whereas elevated neutrophils were found in
later-occurring rejection (>180 days after transplant-
ation) [37].
In addition, many studies compared BAL and plasma
samples to the histological pattern in TBB. However,
whereas a direct relationship between the BAL profile
and the severity of grade A (cellular) and B (lymphocytic
bronchiolitis) rejection on concurrent TBB samples has
been shown [41], some studies did not make a clear dis-
tinction between these grades. As illustrative example,
Patil et al. merged grade A and B scores in their cumula-
tive scoring system, while the semi-quantitative scoring
system by Tikkanen and colleagues did not distinguish
between inflammation of the alveolar and bronchiolar
compartment [37, 44]. These approaches make it impos-
sible to assess BAL cellularity according to separate
grade A or B severity scores and to directly compare the
results between both studies.
Furthermore, in most studies surrogate markers have
been analysed separately, impeding further conclusions.
Calculating a composite score, which takes into account
several inflammatory cells, might provide further in-
sights but is beyond the scope of this descriptive review.
Taken together, these factors limit comparability, conclu-
sions and direct translation of these findings in a clinical
setting.
Conclusions
Specific changes in differential cytology of BAL and
plasma samples during acute lung AR have been identi-
fied. Data from blood analysis remain weak with only
few studies assessing cytological changes in peripheral
blood during acute AR.
The illustrative algorithm in Fig. 1 summarizes the
most important findings of this review and assesses the
likelihood of acute AR depending on blood and BAL
analysis. A decline of FEV1 > 10 % should prompt
imaging to exclude confounding factors such as
pneumothorax or bronchial stenosis. Differential cellu-
larity profile in BAL and, of lesser value, in blood sam-
ples might raise suspicion for the presence of acute AR.
In detail, lymphocytosis > 20 %, neutrophilia ≥ 12 % with-
out microbiological evidence for infection as well as the
presence of eosinophils and basophils in BAL might pro-
vide hints for the presence of acute AR. The definite
diagnosis of acute AR, however, still relies on lung
biopsy.
BAL differential cytology might be more powerful in
the context of CLAD than of AR since the presence of
distinct cells (e.g. eosinophils) was found to be associ-
ated with worse outcome and shorter CLAD-free sur-
vival. Future research should, among others, focus on a
composite score that includes several inflammatory cells
in order to enhance the diagnostic value of BAL cell
composition.
In conclusion, when used within the clinical context,
BAL and serum samples might be useful to assist in
decision-making and alter the likelihood for the presence
or absence of acute lung AR. Of note, BAL and serum
samples are no substitutes for transbronchial biopsies in
the evaluation of lung function decline in lung trans-
plant recipients.
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